Clinical Trial Update: Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial (Chemo-IO ACCIO) is evaluating adding an immunotherapy agent to standard chemotherapy for non-small cell lung cancer, currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Lung Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Immunotherapy (PD-1/PD-L1 inhibitor) in combination with chemotherapy (PD-1/PD-L1 inhibitor)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma | Phase 3 | Status: RECRUITING